Prostate cancer early detection

Clinical practice guidelines in oncology™

Mark H. Kawachi, Robert R. Bahnson, Michael Barry, J. Erik Busby, Peter R. Carroll, H. Ballentine Carter, William J. Catalona, Michael S. Cookson, Jonathan I. Epstein, Ruth B. Etzioni, Veda N. Giri, George P. Hemstreet, Richard J. Howe, Paul H. Lange, Hans Lilja, Kevin R. Loughlin, James Mohler, Judd Moul, Robert B. Nadler, Stephen G. Patterson & 4 others Joseph C. Presti, Antoinette M. Stroup, Robert Wake, John T. Wei

Research output: Contribution to journalReview article

89 Citations (Scopus)

Abstract

Since the early 1990s, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, these guidelines recommend ways that individuals and their physicians can use these new techniques rationally for early detection of prostate cancer. These guidelines are not designed to provide an argument for using population screening programs for prostate cancer, but are meant to provide a vehicle for practicing early detection efforts in an evidence-based, systematic fashion in patients who choose to participate in these programs. Whether to treat a patient on diagnosis is beyond the scope of these guidelines (see NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer [in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org]). These guidelines incorporate many new validated findings in addition to the DRE and tPSA test, including percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical efficacy of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation. The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program for early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient's need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances.

Original languageEnglish (US)
Pages (from-to)240-262
Number of pages23
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume8
Issue number2
DOIs
StatePublished - Jan 1 2010

Fingerprint

Practice Guidelines
Prostatic Neoplasms
Guidelines
Biopsy
Early Detection of Cancer
Prostate
Population Control
Biomarkers
Exercise
Pathology
Physicians

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kawachi, M. H., Bahnson, R. R., Barry, M., Busby, J. E., Carroll, P. R., Carter, H. B., ... Wei, J. T. (2010). Prostate cancer early detection: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 8(2), 240-262. https://doi.org/10.6004/jnccn.2010.0016

Prostate cancer early detection : Clinical practice guidelines in oncology™. / Kawachi, Mark H.; Bahnson, Robert R.; Barry, Michael; Busby, J. Erik; Carroll, Peter R.; Carter, H. Ballentine; Catalona, William J.; Cookson, Michael S.; Epstein, Jonathan I.; Etzioni, Ruth B.; Giri, Veda N.; Hemstreet, George P.; Howe, Richard J.; Lange, Paul H.; Lilja, Hans; Loughlin, Kevin R.; Mohler, James; Moul, Judd; Nadler, Robert B.; Patterson, Stephen G.; Presti, Joseph C.; Stroup, Antoinette M.; Wake, Robert; Wei, John T.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 8, No. 2, 01.01.2010, p. 240-262.

Research output: Contribution to journalReview article

Kawachi, MH, Bahnson, RR, Barry, M, Busby, JE, Carroll, PR, Carter, HB, Catalona, WJ, Cookson, MS, Epstein, JI, Etzioni, RB, Giri, VN, Hemstreet, GP, Howe, RJ, Lange, PH, Lilja, H, Loughlin, KR, Mohler, J, Moul, J, Nadler, RB, Patterson, SG, Presti, JC, Stroup, AM, Wake, R & Wei, JT 2010, 'Prostate cancer early detection: Clinical practice guidelines in oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 8, no. 2, pp. 240-262. https://doi.org/10.6004/jnccn.2010.0016
Kawachi, Mark H. ; Bahnson, Robert R. ; Barry, Michael ; Busby, J. Erik ; Carroll, Peter R. ; Carter, H. Ballentine ; Catalona, William J. ; Cookson, Michael S. ; Epstein, Jonathan I. ; Etzioni, Ruth B. ; Giri, Veda N. ; Hemstreet, George P. ; Howe, Richard J. ; Lange, Paul H. ; Lilja, Hans ; Loughlin, Kevin R. ; Mohler, James ; Moul, Judd ; Nadler, Robert B. ; Patterson, Stephen G. ; Presti, Joseph C. ; Stroup, Antoinette M. ; Wake, Robert ; Wei, John T. / Prostate cancer early detection : Clinical practice guidelines in oncology™. In: JNCCN Journal of the National Comprehensive Cancer Network. 2010 ; Vol. 8, No. 2. pp. 240-262.
@article{6f38ed54350847d6bb7f1f5c20c6f5b1,
title = "Prostate cancer early detection: Clinical practice guidelines in oncology™",
abstract = "Since the early 1990s, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, these guidelines recommend ways that individuals and their physicians can use these new techniques rationally for early detection of prostate cancer. These guidelines are not designed to provide an argument for using population screening programs for prostate cancer, but are meant to provide a vehicle for practicing early detection efforts in an evidence-based, systematic fashion in patients who choose to participate in these programs. Whether to treat a patient on diagnosis is beyond the scope of these guidelines (see NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer [in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org]). These guidelines incorporate many new validated findings in addition to the DRE and tPSA test, including percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical efficacy of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation. The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program for early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient's need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances.",
author = "Kawachi, {Mark H.} and Bahnson, {Robert R.} and Michael Barry and Busby, {J. Erik} and Carroll, {Peter R.} and Carter, {H. Ballentine} and Catalona, {William J.} and Cookson, {Michael S.} and Epstein, {Jonathan I.} and Etzioni, {Ruth B.} and Giri, {Veda N.} and Hemstreet, {George P.} and Howe, {Richard J.} and Lange, {Paul H.} and Hans Lilja and Loughlin, {Kevin R.} and James Mohler and Judd Moul and Nadler, {Robert B.} and Patterson, {Stephen G.} and Presti, {Joseph C.} and Stroup, {Antoinette M.} and Robert Wake and Wei, {John T.}",
year = "2010",
month = "1",
day = "1",
doi = "10.6004/jnccn.2010.0016",
language = "English (US)",
volume = "8",
pages = "240--262",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "2",

}

TY - JOUR

T1 - Prostate cancer early detection

T2 - Clinical practice guidelines in oncology™

AU - Kawachi, Mark H.

AU - Bahnson, Robert R.

AU - Barry, Michael

AU - Busby, J. Erik

AU - Carroll, Peter R.

AU - Carter, H. Ballentine

AU - Catalona, William J.

AU - Cookson, Michael S.

AU - Epstein, Jonathan I.

AU - Etzioni, Ruth B.

AU - Giri, Veda N.

AU - Hemstreet, George P.

AU - Howe, Richard J.

AU - Lange, Paul H.

AU - Lilja, Hans

AU - Loughlin, Kevin R.

AU - Mohler, James

AU - Moul, Judd

AU - Nadler, Robert B.

AU - Patterson, Stephen G.

AU - Presti, Joseph C.

AU - Stroup, Antoinette M.

AU - Wake, Robert

AU - Wei, John T.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Since the early 1990s, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, these guidelines recommend ways that individuals and their physicians can use these new techniques rationally for early detection of prostate cancer. These guidelines are not designed to provide an argument for using population screening programs for prostate cancer, but are meant to provide a vehicle for practicing early detection efforts in an evidence-based, systematic fashion in patients who choose to participate in these programs. Whether to treat a patient on diagnosis is beyond the scope of these guidelines (see NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer [in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org]). These guidelines incorporate many new validated findings in addition to the DRE and tPSA test, including percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical efficacy of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation. The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program for early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient's need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances.

AB - Since the early 1990s, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, these guidelines recommend ways that individuals and their physicians can use these new techniques rationally for early detection of prostate cancer. These guidelines are not designed to provide an argument for using population screening programs for prostate cancer, but are meant to provide a vehicle for practicing early detection efforts in an evidence-based, systematic fashion in patients who choose to participate in these programs. Whether to treat a patient on diagnosis is beyond the scope of these guidelines (see NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer [in this issue; to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org]). These guidelines incorporate many new validated findings in addition to the DRE and tPSA test, including percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical efficacy of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation. The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program for early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient's need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances.

UR - http://www.scopus.com/inward/record.url?scp=77649099098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649099098&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2010.0016

DO - 10.6004/jnccn.2010.0016

M3 - Review article

VL - 8

SP - 240

EP - 262

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 2

ER -